COHANCECohance Lifesciences Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 1.8 this quarter.
Momentum from moving averages, Supertrend and RSI.
8 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
8 found · risk severe
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹477 Cr | ₹2 Cr | -3.10% | 0.48% | ₹0.40 | -0.3x |
| Q1 FY2027 | ₹422 Cr | ₹-45 Cr | -11.46% | -10.70% | ₹-0.63 | -5.4x |
| Q4 FY2026 | ₹619 Cr | ₹8 Cr | 7.66% | 1.34% | ₹0.51 | 3.2x |
| Q3 FY2026 | ₹545 Cr | ₹29 Cr | 8.89% | 5.33% | ₹0.96 | 5.5x |
| Q2 FY2026 | ₹556 Cr | ₹66 Cr | 13.85% | 11.95% | ₹1.94 | 10.6x |
| Q1 FY2026 | ₹549 Cr | ₹46 Cr | 12.17% | 8.45% | ₹1.28 | 7.2x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.